Yancheng

Researchers are evaluating how well teduglutide works in Chinese adults with short bowel syndrome SBS who depend on parenteral support. The study aims to see how much teduglutide can reduce the need for parenteral support and to understand how the body absorbs, processes, and clears the drug. This is a Phase 3, open-label study focused on treatment outcomes over 24 weeks. Participants will receive a daily injection of teduglutide at a dose of 0.05 mg per kilogram under the skin, injected into one of four areas on the abdomen, thigh, or arm. The treatment period lasts 24 weeks, followed by a safety monitoring phase that continues for another 24 weeks. The entire study duration for each participant is about 65 weeks. During the study, participants will be regularly assessed for changes in their weekly parenteral support volume, safety, and how teduglutide moves through the body. Tests include blood plasma measurements, urine output, body weight, and monitoring for any adverse events. Researchers will closely track treatment effects and safety up to 48 weeks after the initial treatment period to understand long-term impacts.

Researchers are evaluating the safety and effectiveness of low-dose tenecteplase in elderly patients aged 70 and older who have experienced an acute ischemic stroke. This multicenter, randomized controlled trial focuses on treatment within 4.5 hours of stroke onset to assess how this therapy may improve neurological outcomes compared to a standard dose. Participants are randomly assigned to receive either a low dose 0.175 mgkg, up to 17.5 mg or a standard dose 0.25 mgkg, up to 25 mg of tenecteplase given intravenously. The study is designed as a parallel-group trial comparing these two dosing regimens to understand which may be more beneficial and safe for elderly stroke patients. Participants will be monitored for recovery and safety through neurological assessments using scales such as the Modified Rankin Scale and the National Institutes of Health Stroke Scale up to 90 days after treatment. Outcomes like neurological improvement, functional independence, quality of life, and any bleeding events will be closely measured. The trial will continue until December 2028, with follow-up visits planned to evaluate participants progress and overall health.